Michael Fuchs

8PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Haematological tumoursAutoimmunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|May 13, 2025
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Dennis A Eichenauer, Aylin Basaran, Ina Bühnen

|Mar 28, 2024
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma-A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group.

Michael Oertel, Priska Hölscher, Dominik Hering

|Jul 14, 2023
Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?

Dennis A Eichenauer, Michael Fuchs

|Dec 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.

Paul J Bröckelmann, Ina Bühnen, Julia Meissner

|Oct 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.

Paul J Bröckelmann, Horst Müller, Teresa Guhl

Pageof 2

Frequent Collaborators

5 joint publications

Peter Borchmann

4 joint publications

Paul Jan Bröckelmann

4 joint publications

Bastian von Tresckow

3 joint publications

Christian Baues